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Interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-a) are important multifunctional cytokines involved in tumour growth and
metastasis. In this study, we have measured serial levels of serum IL-6 and TNF-a in prostate cancer patients. A total of 80 patients
with carcinoma of the prostate and 38 controls were studied. Three patient groups, with small bulk localised, large volume localised
and metastatic prostate cancer, were assessed. Serum IL-6 and TNF-a levels were measured and correlated with clinicopathological
variables and patient survival. Serial changes in these cytokines were also assessed and related to disease progression in 40 patients
with recurrent prostate cancer. Serum IL-6 levels in patients with metastatic disease (9.377.8pgml
 1) were higher than those in
patients with localised disease (1.370.8pgml
 1, Po0.001). Significantly elevated levels of TNF-a were found in metastatic disease
(6.373.6pgml
 1) compared with localised disease (1.170.5pgml
 1, Po0.001). The levels of both cytokines were directly
correlated with the extent of the disease. Serial analysis in 40 patients with recurrent tumours showed that both cytokines became
elevated at the point of prostate-specific antigen progression. In conclusion, these results suggest that IL-6 and TNF-a correlate with
the extent of disease in patients with prostate cancer and may be monitored in conjunction with other disease markers.
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Prostate cancer is the most common cancer in men in the Western
world and the second most common cause of male cancer deaths.
The progression of prostate cancer to a metastatic state and to
hormone independence is thought of as a multi-step process
involving growth factors, hormones and cytokines (Bok and Small,
2002; Huss et al, 2003).
Although there are clear descriptions of the relationship of
cytokines to the development and progression of many cancers,
there are few published observations relevant to prostate cancer.
Surprisingly perhaps for a tumour where there is such clear evidence
of a primary hormonal basis to its development, there is emerging
evidence of cytokine involvement. IL-6 and TNF-a, two cytokines
with multiple and overlapping biological properties, are involved in
prostate cancer development (Shariat et al, 2001; Smith et al, 2001).
This involvement of IL-6 at a cellular level with the processes of
cancer control is reflected by the results of serum studies of cancer
patients, where IL-6 may reflect prognosis and tumour load.
Elevated IL-6 levels have been associated with advanced stage and
metastasis-related morbidity (Adler et al, 1999; Nakashima et al,
2000; Wise et al, 2000). Thus, it has been recently reported that
patients with metastatic ovarian cancer and patients with
metastatic renal cell carcinoma have higher serum IL-6 levels than
those without disseminated disease (Blay et al, 1992; Scambia et al,
1995). It has also been demonstrated that elevated IL-6 levels are
associated with a poor prognosis in tumours such as non-small-
cell lung cancer. The ontological role of IL-6 in this process is not
known (De Vita et al, 1998).
Studies of IL-6 in prostate carcinoma provide support for the
hypothesis that direct local production of IL-6 by malignant cells
significantly contributes to elevated serum levels (Deeble et al,
2001).
IL-6 and TNF-a are considered the major mediators of a network
of interactive signals. TNF-a is a pleiotropic cytokine, which like IL-
6 has been shown to be associated with cancer progression. It is of
interest that many androgen-insensitive prostate cancer cells are
TNF-a insensitive. This may be because of the upregulation of a
series of antiapoptotic genes involved in a network of paracrine and
autocrine loops that modulate prostate carcinoma cell activity, and
these include the nuclear factor-kappab (NF-kb) family of
transcription factors (Muenchen et al, 2000).
In a series of 122 patients with renal cell carcinoma, Yoshida et al
(2002) demonstrated that serum levels of TNF-a directly correlated
with advanced stage grouping as compared with controls, and
suggested that TNF-a could be useful in the early diagnosis of the
disease. There has been a single study by Nakashima et al (1998),
where TNF-a has been shown to be associated with prostate cancer
progression. Serum TNF-a activity was positive in 76% of the
patients with relapsed disease who had a significantly higher
mortality rate than those with undetectable serum TNF-a levels.
In this study, we measured the serum levels of IL-6 and TNF-a in
prostate cancer patients, using a highly sensitive ELISA kit, in an
attempt to define their association with clinicopathological
features and clinical outcome.
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lMATERIALS AND METHODS
Patients
A total of 80 men with prostate cancer (mean age 74.577.5 years)
were included in this prospective study and compared with two
normal control groups, consisting of 12 men presenting for
prostate cancer screening who had no prior history of cancer or
chronic disease, a normal digital rectal examination and a
prostate-specific antigen (PSA) of less than 2.0ngml
 1, which is
in the PSA range with an estimated prostate cancer detection
probability of less than 1% in the first 4 years after screening
(Smith et al, 1996), and 26 patients with biopsy-proven benign
prostatic hyperplasia (1).
The mean control age was 67.576.8 years. All patients had
histological confirmation of the diagnosis of prostate cancer by
needle biopsy or by transurethral resection of the prostate. Each
patient was staged by clinical examination, bone scanning and
computed tomography of the abdomen and pelvis. For the
histologic grade the Gleason scoring was used. No patients had
evidence of active infection or inflammatory disease.
To further evaluate the association between IL-6 and TNF-a and
the progression of the disease, we assessed the serial changes of
both cytokines in patients with recurrent disease. Therefore, at the
time of the study, three samples from each patient with locally
advanced or metastatic cancer were collected. The samples were
chosen to represent the time points of presentation prior to
treatment, the first evidence of PSA increase beyond the normal
range and disease progression.
Out of 26 patients with localised disease, 12 were initially treated
with radiation therapy or surgery, whereas all patients with locally
advanced or metastatic disease were treated with endocrine
therapy using a luteinising hormone-releasing analogue and
flutamide. Neither patients with metastatic disease nor patients
with localised disease were treated before serum collection.
Sample collection and cytokine measurements
Blood samples were prospectively collected with the appropriate
Ethical Committee permissions, from patients attending Oncology
Outpatients Clinics at the Hammersmith Hospital. Each sample
had been collected in a Vacutainer, (Becton Dickinson, Plymouth,
UK) and serum was separated within 1h of blood collection after
spinning for 15min at 1500g. The serum was stored without
preservative at  701C and then thawed just prior to testing (2).
Serum IL-6 and TNF-a concentrations were determined using
the commercially available enzyme-linked immuno-sorbent assay
(ELISA), US (Ultra sensitive), kit supplied by Biosource Interna-
tional (CA, USA). The assays employ the quantitative sandwich
enzyme immunoassay technique using recombinant human IL-6
and TNF-a, with antibodies raised against the recombinant
proteins, respectively. The IL-6 ELISA assay has a performance
sensitivity of less than 0.16pgml
 1 with the minimum detectable
level at 104fgml
 1. The TNF-a assay has a performance sensitivity
of less than 0.5pgml
 1 and the minimum detectable level was
0.09pgml
 1. Optical density was read with a microtiter plate
reader by dual wavelength at 450nm. All samples were assayed in
duplicate.
Elevated serum levels of the studied cytokines were defined as
being greater than the 95th percentile values in the healthy control
group. This resulted in a cutoff value of 2.1 and 1.9pgml
 1 for IL-6
and TNF-a, respectively.
Follow-up
Follow-up data were obtained for all patients. Details of clinical
progress and survival were obtained from Hospital and General
Practice records and traced to Death Certificates where appro-
priate. Biochemical progression was described as that point when
PSA levels exceeded 0.2ngml
 1 on two or more occasions. The
date of progression was assigned as the date of the first value
greater than 0.2ngml
 1.
The overall survival (OS) time was calculated for each patient to
the nearest month, taken from the time of presentation to the time
or death/last recorded follow-up. The median time of follow up
was 48 months.
Statistical analysis
The Kruskal–Wallis analysis of variance (ANOVA) was applied to
evaluate differences in cytokine levels between unpaired and
paired multiple group observations. Logistic regression analysis
and the general linear model for repeated measurements were
performed to assess the significance of changes in serial
measurements of cytokines in individual patients at presentation,
and relapse. Differences in the cytokines levels among clinical and
pathologic features were tested by use of the Mann–Whitney test.
Spearman’s rank correlation coefficient was used to compare the
ordinal and continuous variables. The Kaplan–Meier method was
used to calculate survival functions, and differences were assessed
by log-rank analysis. Multivariate survival analysis was performed
using the Cox proportional regression model. Significance was
presumed at values of Po0.05.
Statistical analysis was performed with the Statistical Package
for the Social Sciences (SPSS) statistical software package version
10.0 for Windows.
RESULTS
Clinical and pathologic characteristics
In all, 26 patients (33%) had localised small volume (T1, T2, N0,
M0) cancers confined to the prostate, 14 patients (17%) had bulky
(T3, T4, N0, M0) locally advanced disease and 40 patients (50%),
had metastatic disease. The patients’ characteristics are sum-
marised in Table 1.
The Gleason score was 2–4 in 12 patients (14%), 5–6 in 50
patients (63%) and 7–10 in 18 patients (23%). The median PSA
levels in patients with localised disease were 5.2ngml
 1 (range
1.86–15.8), 19.2ngml
 1 (range 8.6–96.7) and 113.5ngml
 1 (range
23.7–450.2), in patients with locally advanced and metastatic
disease, respectively (2).
Baseline serum levels of cytokines in controls and prostate
cancer patients
Both IL-6 and TNF-a were detectable in all control subjects and
prostate cancer patients. In all of the prostate cancer patients, IL-6
and TNF-a levels were 5.676.7 and 4.373.6pgml
 1, respectively,
and significantly higher than the controls (1.170.6 and
1.270.4pgml
 1, respectively, P¼0.031 and 0.003) (Table 2).
When results from the three groups of patients with cancer were
individually compared with the controls and patients with BPH,
IL-6 levels were significantly higher in patients with metastatic
disease (mean 9.377.8pgml
 1, median 7.0pgml
 1, Po0.001).
Significantly elevated levels of TNF-a were found in patients with
bulky locally advanced (mean 3.973.4pgml
 1, median
2.2pgml
 1) and metastatic disease (mean 6.373.6pgml
 1,
median 6.0pgml
 1) as compared with controls (mean
1.170.5pgml
 1, median 0.9pgml
 1)( P¼0.05 and Po0.001,
respectively), but not in patients with localised small volume
prostate cancer (Table 2).
When patients with metastatic prostate cancer were compared
with both groups of patients with localised prostate cancer, there
were significant differences in IL-6 and TNF-a levels among
the groups. The group of patients with lymph node metastases or
Serum IL-6 and TNF-a and prostate cancer progression
V Michalaki et al
2313
British Journal of Cancer (2004) 90(12), 2312–2316 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lbone metastases had similar IL-6 and TNF-a levels (P¼0.31 and
P¼0.28), which were higher than those in the group with localised
disease (Po0.001).
Serum IL-6 and TNF-a levels were significantly elevated in
patients with Gleason score 46 (mean 7.875.3pgml
 1, median
4.0pgml
 1, P¼0.001 with respect to IL-6; mean 5.273.7pgml
 1,
median 5.1pgml
 1, P¼0.009 with respect to TNF-a).
Univariate analysis showed a positive correlation between
disease stage and IL-6 and TNF-a levels (IL-6: correlation
coefficient, 0.32; Po0.001; TNF-a: correlation coefficient 0.29;
P¼0.008). TNF-a levels were also correlated with PSA (correlation
coefficient, 0.41; Po0.001).
To identify the variables of prognostic significance in all of the
patients with prostate cancer, univariate analysis of each variable
was performed in relation to the survival time. On univariate Cox
proportional hazards regression analysis (Table 3), serum IL-6
(above the cutoff level of 2.1pgml
 1) and serum TNF-a (above the
cutoff level of 1.9pgml
 1) were significant prognostic factors for
survival, along with Gleason sum and serum PSA (categorised as
4100ngml
 1; Figure 1).
By the log-rank test, we found that patients with localised
disease and serum IL-6 levels above the cutoff level (2.1pgml
 1)
had an increased probability of poor overall survival. Similarly, the
same group of patients with serum TNF-a levels above the cutoff
level (1.9pgml
 1) had the worst outcome (P¼0.04; Figure 2).
However, the multivariate regression analysis failed to confirm
these cytokines as significant independent prognostic variables for
cancer-specific survival.
Serial changes in levels of cytokines at presentation, PSA
progression and symptom progression
To further evaluate the association between IL-6 and TNF-a and
the progression of the disease, we additionally assessed the serial
changes of these cytokines in 40 patients with bulky locally
advanced or metastatic cancer, at the time points of presentation
prior to treatment, at the first time point when PSA started to rise
and the point at which there was progression to symptomatic
recurrent disease with bone pain or increased obstructive urinary
symptoms (Figure 3).
Analysis of the serial measurements revealed significant
differences in both cytokines during the evolution of the disease.
The levels of each cytokine were significantly higher at the time
points of PSA progression compared with the baseline levels. All
patients with symptomatic progressive disease had significantly
higher levels of IL-6 (mean 9.377.0, Po0.01) and TNF-a (mean
6.273.6, Po0.01) than at presentation (mean 1.170.7, Po0.021
and 1.370.6, Po0.026 for IL-6 and TNF-a, respectively), or than at
the point of biochemical relapse (mean 3.171.47, Po0.001 and
4.573.4, Po0.01 for IL-6 and TNF-a, respectively).
Table 2 Serum levels of IL-6 and TNF-a in all prostate cancer patients and controls according to stage
95% confidence intervals
nP -value
a Mean7s.d. Lower bound Upper bound
IL-6 (pgml
 1) P. cancer 80 0.031 (vs controls) 5.6576.74 4.15 7.15
(all)_
Localised 26 o0.001 (vs metastatic) 1.2770.81 0.93 1.59
Locally adv. 14 0.001 (vs metastatic) 3.5072.88 1.82 5.16
Metastatic 40 o0.001 (vs controls) 9.2677.81 6.76 11.7
Controls 12 1.1370.63 0.73 1.53
BPH 26 1.2070.49 1.00 1.40
TNF-a(pgml
 1) P. cancer 80 0.003 (vs controls) 4.3073.69 3.47 5.12
(all)_
Localised 26 0.03 (vs metastatic) 1.3870.69 1.10 1.66
Locally adv. 14 0.02 (vs metastatic) 3.9073.43 1.90 5.87
Metastatic 40 o0.001 (vs controls) 6.3473.66 5.16 7.51
Controls 12 1.0870.55 0.73 1.43
BPH 26 1.2170.65 0.94 1.47
aMann–Whitney U test.
Table 1 Patients’ characteristics
Patients
No %
Clinical stage
T1a 4 5
T1b+c 7 8.8
T2a 8 10
T2b 4 5
T2c 3 3.8
T3 9 11.2
T4 5 6.2
M1 40 50
Gleason score
2–4 12 14
5–6 50 63
7–10 18 23
Table 3 Univariate and multivariate Cox regression analysis for
predictors of survival in prostate cancer patients with localised disease
Univariate Multivariate
Hazards ratio P Hazards ratio P 95% CI
Gleason score 10.53 o0.0001 8.98 o0.0001 2.92–28.75
IL-6
a 3.6 0.031 2.1 0.053 097–5.45
TNF-a
a 1.9 0.042
PSA
b 5.2 o0.01
aTNF-a categorised as above or below the cutoff level of 1.9pgml
 1. IL-6 categorised
as above or below the cutoff level of 2.1pgml
 1.
bPSA was categorised as 4or
o100ngml
 1.
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cytokines were significant predictors for the evolution of the
disease. Thus, considering the baseline IL-6 levels, the relative risk
for development of biochemical progression was 1.9 (95% CI,
1.088–3.281; P¼0.024). Similarly, for TNF-a the relative risk was
slightly higher at 2.1 (95% CI, 1.144–4.12; P¼0.018).
DISCUSSION
Elevated serum levels of specific cytokines have been previously
described in prostate cancer benign prostate hyperplasia speci-
mens and in prostate cancer cell lines (Chen et al, 2000; Mizokami
et al, 2000).
Twillie et al (1995) showed elevated serum IL-6 levels in 47% of
73 patients with advanced hormone refractory prostate cancer and
suggested that this cytokine mediated morbidity in patients with
metastatic disease. Likewise, Drachenberg et al (1999) reported
high concentrations of IL-6 in men with hormone refractory
prostate cancer compared to normal controls, benign prostatic
hyperplasia, prostatitis and localised or recurrent disease.
We report elevated serum levels of the cytokines IL-6 and TNF-a
in patients with prostate cancer as compared with controls. There
was a strong association between the serum levels of the cytokines,
disease stage and the presence of metastatic disease. TNF-a was
significantly elevated in patients with metastatic cancer compared
with the two groups of patients with localised disease and controls,
and was correlated with increasing PSA. In contrast, IL-6 was
correlated with tumour burden independently of PSA.
In patients with progressive disease, both IL-6 and TNF-a were
elevated at the point of biochemical progression and further raised
at symptomatic progression. These cytokines may therefore
provide additional markers to PSA that reflect the activity of
prostate cancer.
Our results confirm the findings of previous studies and add to
the literature by documenting the significance of IL-6 and TNF-a
as predictors of progressive disease.
We postulate that serum IL-6 and TNF-a levels might be useful
prognostic markers with regard to progression to biochemical or
symptomatic relapse based on the results of serial measurements.
To our knowledge, this is the first time in the reported literature
that monitoring of serial serum concentrations of these cytokines
has been suggested as possible indicators of disease progression.
However, the multivariate regression analysis failed to confirm
these cytokines as significant independent prognostic variables for
patient survival.
IL-6 is known to promote the proliferation and metastatic
potential of cancer cells.
This cytokine has been characterised as a prostate exocrine gene
product that interacts with its receptor in prostate cells, regulating
proliferation and differentiation, and in prostate cancer cell lines
activates androgen receptor (AR).
IL-6 signalling is mediated through the Janus kinase (JAK),
signal transducer, activator of transcription 3 (STAT3) and
mitogen-activated protein kinase (MAPK), which induces AR-
mediated gene activation in prostate cancer (Hobisch et al, 1998;
Lou et al, 2000; Spiotto and Chung, 2000). Several in vitro studies
on prostate cancer cell lines suggest that prostate cancer cells
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Figure 1 Disease-specific survival in patients with localised prostate
cancer, stratified into groups above or below the cutoff IL-6 level of
2.1pgml
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patients.
Serum IL-6 and TNF-a and prostate cancer progression
V Michalaki et al
2315
British Journal of Cancer (2004) 90(12), 2312–2316 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lthemselves are secreting a major portion of IL-6, although
other sources cannot be excluded. As prostate cancer cells
also express high levels of IL-6 receptor, IL-6 may elicit both
paracrine and autocrine responses. Thus, during the progression
of prostate cancer to the hormone refractory phenotype,
IL-6 undergoes a functional transition from paracrine growth
inhibitor to autocrine growth stimulator (Hobisch et al,
1998; Deeble et al, 2001). These androgen-insensitive cells are
also TNF-a insensitive. This is attributed to the constitutive
activation of antiapoptotic genes, since TNF-a activates cell
survival and cell death mechanisms simultaneously and can
influence cell growth by apoptotic and nonapoptotic mechanisms
(Muenchen et al, 2000).
However, many signalling pathways through which IL-6 and
TNF-a mediate their effects have not been defined yet. A better
understanding of how these cytokines contribute to the patho-
physiology of prostate cancer would provide new targets for
therapeutic intervention.
In conclusion, viewed in the context of similar observations
made for other cancers, these data further support a relationship
between elevated IL-6 and TNF-a levels and metastatic prostate
cancer. Both cytokines correlate with the extent of disease and
should be monitored in conjunction with other disease indicators.
Although it is possible that these cytokines have a casual role in
cancer progression, it is also of course clear that they may have a
bystander role in malignancy.
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